Very true but I also can't help but think there will be too many key inflection points this year. I believe we're expecting first patient dosed/read out data for in-human trials for both FTO and Cardio protection this year, and a myriad of preclinical work too. Rhetoric has certainly stepped up re: partnerships and BP engagement and the BoD are taking the requisite steps with the two recent additions. I think there will certainly be a series of big announcements this year, the question is how will the market react. Assuming everything is largely on schedule, and clinical success continues, I am predicting SP appreciation in 2023, and our final transaction hopefully in 2024. IMO - DYOR
Very true but I also can't help but think there will be too many...
-
- There are more pages in this discussion • 5,688 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |